XML 68 R58.htm IDEA: XBRL DOCUMENT
v3.25.1

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - LadRx (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Jun. 21, 2023 | Jun. 30, 2024 | Mar. 31, 2025 | Mar. 31, 2024 | Dec. 31, 2024
Agreements |  |  |  |  |
Contingent consideration under RPAs, AAAs, and CPPAs |  |  |  |  | $ 3,000
Payments of consideration under RPAs, AAAs and CPPAs |  |  | $ 8,000 | $ 15,000 |
Long-term royalty and commercial payment receivables under the cost recovery method |  |  | 59,916 |  | 55,936
Receipts under RPAs, AAAs, and CPPAs |  |  | 1,307 | $ 7,771 |
Short-term royalty and commercial payment receivables under the cost recovery method |  |  | 413 |  | 413
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement |  |  |  |  |
Agreements |  |  |  |  |
Amount of regulatory milestone payment removed |  | $ 4,000 |  |  |
Payments of consideration under RPAs, AAAs and CPPAs | $ 5,000 |  |  |  |
Maximum regulatory and commercial sales milestone payments | 6,000 |  |  |  |
Maximum regulatory milestone payments | 5,000 |  |  |  |
Maximum commercial sales milestone payments | 1,000 |  |  |  |
Long-term royalty and commercial payment receivables under the cost recovery method | 6,000 |  |  |  |
Receipts under RPAs, AAAs, and CPPAs |  |  | 400 |  |
Short-term royalty and commercial payment receivables under the cost recovery method |  |  | 400 |  |
Allowance for credit losses |  |  | $ 0 |  | 0
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones |  |  |  |  |
Agreements |  |  |  |  |
Contingent consideration under RPAs, AAAs, and CPPAs | $ 1,000 |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  |  |  | 1,000
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Sales-based milestones |  |  |  |  |
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  |  |  | $ 1,000
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Aldoxorubicin | Regulatory milestones |  |  |  |  |
Agreements |  |  |  |  |
Contingent consideration under RPAs, AAAs, and CPPAs |  | $ 0 |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderPurchaseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Increase (decrease) in potential amount payable on regulatory milestone. + References No definition available. + Details
Name: | xoma_IncreaseDecreaseInPotentialAmountPayableOnRegulatoryMilestone
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in agreements, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. + References No definition available. + Details
Name: | xoma_MaximumPayableOnRegulatoryMilestone
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + References No definition available. + Details
Name: | xoma_MaximumPayableOnSalesMilestone
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + References No definition available. + Details
Name: | xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + References No definition available. + Details
Name: | xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. + References No definition available. + Details
Name: | xoma_ReceiptsUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty and commercial payment receivables under cost recovery method probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialPaymentReceivablesCostRecoveryMethodLongTerm
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalty and commercial payment receivables under cost recovery method probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialPaymentReceivablesCostRecoveryMethodShortTerm
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_LadrxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_AldoxorubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |